Form 4: Kymera Therapeutics Exec Trades Shares

Noah Goodman, Chief Business Officer at Kymera Therapeutics, executed a series of stock transactions on June 25, 2026, under a pre-arranged trading plan.

Summary

• Noah Goodman, Chief Business Officer of Kymera Therapeutics, Inc., reported transactions involving common stock on June 25, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on December 10, 2025.
• Goodman acquired 5,000 shares of common stock at a price of $21.05 per share.
• He also disposed of 2,500 shares at $109 per share and another 2,500 shares at $119 per share.
• Following these transactions, Goodman beneficially owns 50,195.438 shares of common stock.
• A stock option to purchase 5,000 shares of common stock at an exercise price of $21.05, with a portion vesting on April 8, 2026, and the remainder vesting monthly over 36 months, is also held.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant share transactions by an executive, the use of a Rule 10b5-1 plan mitigates negative sentiment, indicating a pre-planned strategy rather than an immediate reaction to company news.

Positives

• The acquisition of 5,000 shares at a lower price ($21.05) suggests a potential belief in future value appreciation by the executive.
• The existence of a Rule 10b5-1 trading plan indicates pre-planned, systematic trading activity, which can be viewed positively as it aims to avoid insider trading concerns.

Negatives

• The disposal of 5,000 shares at significantly higher prices ($109 and $119) indicates a realization of profit by the executive.
• The large difference between the acquisition price and disposal prices for the same day's transactions might raise questions about the timing and execution of the trading plan.

Risks

• The disposal of a significant number of shares by a key executive could be interpreted by the market as a lack of confidence in near-term stock performance, although it was executed under a pre-planned trading strategy.
• The vesting schedule of the stock option indicates continued reliance on the executive's continued employment for full benefit realization.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. However, the stock option with a vesting schedule extending over 36 months implies a long-term outlook for the reporting person's continued employment and potential future value of the stock.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025, adopted by the reporting person.
• Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. The use of Rule 10b5-1 plans is a common strategy for insiders to diversify their holdings or manage personal finances while adhering to insider trading regulations. The specific details of the transactions, including prices and volumes, are closely watched by the market for any signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: May interpret the sale of shares as a signal, though mitigated by the Rule 10b5-1 plan. The acquisition at a lower price could be seen as a positive signal.
• Employees: The executive's continued employment is tied to stock option vesting, aligning their interests with the company's long-term performance.
• Management: Demonstrates adherence to regulatory requirements for insider trading through the use of a pre-arranged trading plan.

Next Steps

• Continued vesting of stock options subject to continued employment.
• Potential future transactions under the Rule 10b5-1 plan, depending on its terms and market conditions.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Kymera Therapeutics, KYMR, Stock Options, Beneficial Ownership, Securities Exchange Act, Noah Goodman, Chief Business Officer